sumi.news
Search
Following
Sign in
← Back to news
S
Seeking Alpha: News
RSS Feed
seekingalpha.com/news/all
seekingalpha.com/market_currents.xml
Follow
Latest
Fri Jul 17
Dentsu GAAP EPS of ¥177.58, revenue of ¥717.35B; reaffirms FY 2026 outlook
2d
S
Ebara Corporation GAAP EPS of ¥73.48, revenue of ¥490.76B; updates FY 2026 outlook
2d
B
Nintendo shares gain as ‘Pokopia’ sales top 5 million
2d
B
MS& AD Insurance GAAP EPS of ¥226.82, revenue of ¥1686.19B; reaffirms FY 2027 outlook
2d
B
Companhia Energética de Minas Gerais - CEMIG reports Q2 results
2d
B
Reddit shares jumps on S&P 500 entry; SUI joins MidCap 400
2d
S
BIO-key GAAP EPS of -$0.56, revenue of $1.92M
2d
S
NKT A/S GAAP EPS of €0.93, revenue of €947M; updates FY 2026 outlook
2d
S
Apple partners with Alibaba on custom AI model for China: Reuters
2d
S
Melcor Developments declares CAD 0.15 dividend
2d
S
Murphy USA raises dividend by 1.6% to $0.65
2d
S
MDU Resources raises dividend by 3.6% to $0.145 per share
2d
S
Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share
2d
S
XBP Global targets $65M-$75M in annualized efficiencies while revenue per employee approaches $100,000 by year-end
2d
S
Aveanna hits 52-week high after Q2 beat, guidance hike
2d
S
Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%
2d
S
Asian stocks trade mixed as U.S. inflation cools; Strait of Hormuz risks weigh
2d
S
China's Z.ai readies GLM-5.3 model to rival Anthropic, OpenAI
2d
S
Applied Materials expects $10.25B Q4 revenue amid projected 2026 packaging growth of more than 70%
2d
S
Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026
2d
S
ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 2026
2d
S
Soluna outlines 70%-80% project debt plan for 100-MW AI builds, while expecting 206 MW operating by end of summer
2d
S
Goldman Sachs lines up investors for Nvidia’s $500B AI funding plan - report
2d
S
Valvoline prices upsized $600M senior notes offering at 6.125%
2d
B
Uber, China's Pony.ai plan European robotaxi push with 2,000 vehicles
2d
S
Early OpenAI backer Thrive Capital value hits $3.7B on fund growth, sees 'billions in liquidity': report
2d
S
HeartFlow projects $246M-$250M 2026 revenue as Plaque outlook rises to $29M-$31M
2d
S
Wesdome Gold Mines Non-GAAP EPS of C$0.65, revenue of C$266.76M; updates FY 2026 outlook
2d
B
Martin Marietta Materials raises dividend to $0.84 per share
2d
B
Weyerhaeuser declares $0.21 dividend
2d
B
Cboe Global Markets raises dividend by 19% to $0.86
2d
B
Firm Capital Mortgage Investment declares C$0.078 dividend
2d
B
RCM Technologies Non-GAAP EPS of $0.82 beats by $0.12, revenue of $93.8M beats by $11M
2d
B
Agora Non-GAAP EPS of $0.02, revenue of $40.4M; gives Q3 outlook
2d
B
OpenAI’s revenue run rate tops $40B ahead of planned Wall Street debut: report
2d
S
Innventure signals shift to milestone reporting as Accelsius targets adoption in a projected $9B 2030 two-phase market
2d
S
Celcuity plans late Q3 2026 REVTORPYK shipments and targets sNDA submission in Q3 2026
2d
S
HawkEye 360 outlines $215M-$220M 2026 revenue outlook while targeting 10-minute revisit and latency in 2-3 years
2d
S
Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan
3d
S
Elutia anticipates NXT-41x clearance in 1H 2027 while targeting >80% gross margins at scale
3d
S
Health In Tech reaffirms $45M-$50M 2026 revenue guidance while preparing HitRix launch in the second half
3d
S
AmpliTech outlines 2026 priorities while declining to reaffirm $50M full-year revenue guidance amid deployment timing shifts
3d
B
Blaize forecasts $40M-$43M 2026 revenue amid Starshine reserve and memory inflation
3d
B
Sensus outlines shift to $250,000 average selling price as it targets a stronger second half
3d
B
Rekor targets adjusted EBITDA profitability in H2 2026 as GoSecure expands into audio
3d
S
Tenon outlines sacropelvic launches over next six to nine months following FDA 510(k) clearance
3d
S
Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter
3d
S
Caliber projects $18M-$22M 2026 revenue while expanding tokenization to an initial ~$100M slate of managed assets
3d
S
AudioEye expects over $15M run rate adjusted EBITDA by end of 2026 as it raises full-year adjusted EBITDA guidance to at least $12.7M
3d
S
Jefferson Capital outlines $1.1B expected ERC collections in next 12 months while entering Mexico market
3d
B
More →